Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (SHA:603168)
5.89
-0.11 (-1.83%)
At close: Sep 10, 2026
SHA:603168 Revenue
Zhejiang Shapuaisi Pharmaceutical had revenue of 97.98M CNY in the quarter ending June 30, 2026, a decrease of -27.07%. This brings the company's revenue in the last twelve months to 423.20M, down -12.42% year-over-year. In the year 2025, Zhejiang Shapuaisi Pharmaceutical had annual revenue of 462.78M, down -4.38%.
Revenue (ttm)
423.20M
Revenue Growth
-12.42%
P/S Ratio
5.21
Revenue / Employee
370.58K
Employees
1,142
Market Cap
2.20B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 462.78M | -21.18M | -4.38% |
| Dec 31, 2024 | 483.96M | -161.01M | -24.96% |
| Dec 31, 2023 | 644.97M | 95.43M | 17.37% |
| Dec 31, 2022 | 549.54M | -80.23M | -12.74% |
| Dec 31, 2021 | 629.76M | 282.96M | 81.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ShanXi C&Y Pharmaceutical Group Co.,LTD. | 849.67M |
| Zhejiang Shengda Bio-Pharm | 832.86M |
| Enwei Pharmaceutical | 826.13M |
| Hainan Huluwa Pharmaceutical Group | 634.04M |
| Chengdu huasun technology group Inc. , LTD. | 486.70M |
| Anhui Huangshan Capsule | 407.10M |
| Guhan Pharmaceutical Group | 329.41M |
| Qinghai Spring Medicinal Resources Technology | 303.67M |